Cara Therapeutics, Inc. (0HTC.L)
USD 5.33
(-68.23%)
USD 5.33
(-68.23%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -118.51 Million USD | -42.08% |
| 2022 | -83.41 Million USD | 5.42% |
| 2021 | -88.19 Million USD | -1148.67% |
| 2020 | 8.41 Million USD | 107.91% |
| 2019 | -106.37 Million USD | -43.72% |
| 2018 | -74.01 Million USD | -27.33% |
| 2017 | -58.12 Million USD | -1.48% |
| 2016 | -57.28 Million USD | -132.0% |
| 2015 | -24.69 Million USD | -39.14% |
| 2014 | -17.74 Million USD | -347.77% |
| 2013 | -3.96 Million USD | 36.8% |
| 2012 | -6.27 Million USD | 36.05% |
| 2011 | -9.8 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -20.01 Million USD | 34.79% |
| 2024 Q1 | -30.69 Million USD | 5.07% |
| 2023 Q3 | -28.03 Million USD | 10.95% |
| 2023 Q1 | -25.68 Million USD | 12.57% |
| 2023 FY | -118.51 Million USD | -42.08% |
| 2023 Q2 | -31.47 Million USD | -22.58% |
| 2023 Q4 | -32.33 Million USD | -15.36% |
| 2022 FY | -83.41 Million USD | 5.42% |
| 2022 Q4 | -29.37 Million USD | -30.45% |
| 2022 Q3 | -22.51 Million USD | -471.45% |
| 2022 Q2 | -3.94 Million USD | 85.72% |
| 2022 Q1 | -27.58 Million USD | 17.36% |
| 2021 Q4 | -33.38 Million USD | -3195.36% |
| 2021 Q2 | -30.74 Million USD | -31.95% |
| 2021 FY | -88.19 Million USD | -1148.67% |
| 2021 Q1 | -23.3 Million USD | -129.53% |
| 2021 Q3 | -1.01 Million USD | 96.71% |
| 2020 Q4 | 78.9 Million USD | 577.98% |
| 2020 Q3 | -16.5 Million USD | 34.14% |
| 2020 Q2 | -25.06 Million USD | 13.33% |
| 2020 Q1 | -28.92 Million USD | -1.09% |
| 2020 FY | 8.41 Million USD | 107.91% |
| 2019 Q1 | -21.96 Million USD | -6.33% |
| 2019 FY | -106.37 Million USD | -43.72% |
| 2019 Q2 | -22.96 Million USD | -4.55% |
| 2019 Q3 | -32.84 Million USD | -43.04% |
| 2019 Q4 | -28.61 Million USD | 12.88% |
| 2018 FY | -74.01 Million USD | -27.33% |
| 2018 Q4 | -20.65 Million USD | -6.45% |
| 2018 Q3 | -19.4 Million USD | -12.83% |
| 2018 Q2 | -17.19 Million USD | -2.55% |
| 2018 Q1 | -16.76 Million USD | -18.27% |
| 2017 Q3 | -12.44 Million USD | -33.81% |
| 2017 Q2 | -9.3 Million USD | 58.12% |
| 2017 Q4 | -14.17 Million USD | -13.93% |
| 2017 Q1 | -22.2 Million USD | -1.06% |
| 2017 FY | -58.12 Million USD | -1.48% |
| 2016 Q2 | -13.07 Million USD | -22.29% |
| 2016 FY | -57.28 Million USD | -132.0% |
| 2016 Q4 | -21.97 Million USD | -90.36% |
| 2016 Q3 | -11.54 Million USD | 11.72% |
| 2016 Q1 | -10.69 Million USD | -12.19% |
| 2015 Q3 | -4.78 Million USD | 15.78% |
| 2015 Q2 | -5.68 Million USD | -21.22% |
| 2015 Q1 | -4.68 Million USD | -12.39% |
| 2015 FY | -24.69 Million USD | -39.14% |
| 2015 Q4 | -9.53 Million USD | -99.08% |
| 2014 Q1 | -3.38 Million USD | -61.63% |
| 2014 Q3 | -6.54 Million USD | -79.56% |
| 2014 Q4 | -4.17 Million USD | 36.26% |
| 2014 FY | -17.74 Million USD | -347.77% |
| 2014 Q2 | -3.64 Million USD | -7.74% |
| 2013 Q2 | 5.33 Million USD | 302.77% |
| 2013 Q4 | -2.09 Million USD | 54.25% |
| 2013 Q1 | -2.63 Million USD | -46.47% |
| 2013 FY | -3.96 Million USD | 36.8% |
| 2013 Q3 | -4.57 Million USD | -185.72% |
| 2012 FY | -6.27 Million USD | 36.05% |
| 2012 Q4 | -1.79 Million USD | -53.85% |
| 2012 Q3 | -1.16 Million USD | 0.0% |
| 2011 FY | -9.8 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 61.581% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -118.707% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -33.942% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 109.558% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 66.34% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 73.08% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 21.817% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -149.475% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 57.08% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 50.462% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 170.693% |
| bluebird bio, Inc. | -211.91 Million USD | 44.075% |
| Blueprint Medicines Corporation | -506.98 Million USD | 76.624% |
| Imunon, Inc. | -19.51 Million USD | -507.293% |
| Adicet Bio, Inc. | -142.65 Million USD | 16.925% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 211.657% |
| Dynavax Technologies Corporation | -6.38 Million USD | -1754.954% |
| Editas Medicine, Inc. | -153.21 Million USD | 22.651% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 84.416% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 43.362% |
| Exelixis, Inc. | 207.76 Million USD | 157.042% |
| FibroGen, Inc. | -284.23 Million USD | 58.304% |
| Geron Corporation | -184.12 Million USD | 35.635% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 142.086% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -7.194% |
| Illumina, Inc. | -1.16 Billion USD | 89.792% |
| Incyte Corporation | 597.59 Million USD | 119.832% |
| Insmed Incorporated | -749.56 Million USD | 84.189% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 75.371% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 67.645% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 73.31% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 108.727% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -180.843% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 115.025% |
| Evolus, Inc. | -61.68 Million USD | -92.126% |
| Myriad Genetics, Inc. | -112 Million USD | -5.815% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 147.462% |
| OPKO Health, Inc. | -188.86 Million USD | 37.249% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 77.888% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 9105.547% |
| Verastem, Inc. | -87.36 Million USD | -35.65% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.628% |
| Waters Corporation | 642.23 Million USD | 118.453% |
| Zoetis Inc. | 2.34 Billion USD | 105.056% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 103.274% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.977% |
| Biogen Inc. | 1.16 Billion USD | 110.207% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 54.035% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 102.998% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -165.704% |
| Homology Medicines, Inc. | -53.74 Million USD | -120.518% |
| Nektar Therapeutics | -276.05 Million USD | 57.069% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1035.235% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -37.974% |
| Perrigo Company plc | -12.7 Million USD | -833.173% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -197.323% |